In the life sciences sector, quality does not end with the production of the drug. Distribution also plays a crucial role in ensuring that products reach the end patient in a safe, effective and regulatory compliant condition.
It is in this context that GDP – Good Distribution Practice, a set of basic requirements for the proper management of the distribution chain of medicines, fits in.
In Switzerland, GDP is an essential pillar of the quality surveillance system and is audited by the relevant authorities.
What is GDP (Good Distribution Practice)
Good Distribution Practice is the set of good practice standards governing the storage, transportation and distribution activities of human and veterinary medicines.
The main objective of GDP is to ensure that:
- medicines maintain quality, integrity and traceability throughout the distribution chain;
- risks such as counterfeiting, theft, contamination or deterioration are prevented;
- products are distributed only to authorized parties in accordance with current legislation.
An authoritative reference at the European level is the EU Guidelines on Good Distribution Practice, published by the European Commission and available at the following link:
https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
Although Switzerland is not part of the European Union, these guidelines are also an important reference point for the Swiss context.
The Swiss regulatory framework
The main regulatory reference in Switzerland is the Therapeutic Agents Act (TAA), which can be found on the official website of the Swiss Confederation:
https://www.fedlex.admin.ch/eli/cc/2001/422/it
The LATer is supplemented by ordinances and technical guidelines that define requirements for the distribution of medicines.
The competent supervisory authority is Swissmedic, the Swiss Institute for Therapeutic Products:
- Issues permits for distribution activities;
- Performs GDP inspections;
- Verifies the maintenance of compliance over time.
Official information on distribution and best practices is available directly on Swissmedic’s website:
https://www.swissmedic.ch/swissmedic/it/home/suche.html#medicamenti
Who has to comply with GDP in Switzerland
GDP applies to all operators involved in the distribution of medicines, regardless of the size of the organization or volume of business.
In particular, they must comply with GDP:
- Drug repositories and wholesalers;
- Pharmaceutical companies that directly distribute their own products;
- importers and exporters;
- Logistics operators involved in storage and transportation;
- pharmacies and hospitals, for aspects of receiving, storing and handling medicines.
Even when some activities are outsourced, the responsibility for GDP compliance remains with the permit holder, who must ensure proper qualification and supervision of suppliers.
How to implement GDP correctly
Effective GDP implementation is not limited to the preparation of documentation, but requires a management system that is structured, consistent and proportionate to the activities performed.
1. Quality management system
It is necessary to define a Quality Management System (QMS) that includes:
- standard operating procedures (SOPs);
- Management of deviations and nonconformities;
- CAPA system (corrective and preventive actions);
- Document control and records management.
2. Personnel and training
GDP requires that staff:
- Is properly trained in the principles of good distribution;
- Understand their role in protecting the quality of the medicine;
- Receive documented periodic updates.
A person responsible for GDP, with appropriate skills and experience, must also be formally designated.
3. Premises, equipment and transportation
They must be guaranteed:
- Suitable storage rooms, with control and monitoring of environmental conditions;
- Qualified and maintained equipment;
- Controlled transport processes, including cold chain management, when applicable.
Swissmedic provides specific guidance on transport and storage inspection expectations, available in the official documentation.
4. Traceability, complaints and recalls
A GDP-compliant system must include:
- Full lot traceability;
- Procedures for handling complaints, returns and recalls from the market;
- Measures to prevent the introduction of falsified medicines into the distribution chain.
5. Audit and continuous improvement
Periodic internal audits, audits to critical suppliers, and system reviews enable:
- Identify critical issues in a timely manner;
- Maintaining regulatory compliance;
- Promote continuous improvement of the quality system.
The value of a consultative approach
Implementing GDP effectively means integrating regulatory requirements into day-to-day operational processes, avoiding purely formal approaches.
Specialist support enables Swissmedic’s expectations to be interpreted correctly, building robust, sustainable, inspection-ready systems.
Pharmanomos Sagl supports companies, pharmacies and life sciences operators in implementing and maintaining GDP compliance, turning regulatory obligations into a concrete quality assurance tool.